Antrodia cinnamomea May Interfere with the Interaction Between ACE2 and SARS-CoV-2 Spike Protein in vitro and Reduces Lung Inflammation in a Hamster Model of COVID-19

References

• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi:10.1038/s41586-020-2012-7
   PubMed Web of Science ®Google Scholar
• Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–1448. doi:10.1126/science.abb2762
   PubMed Web of Science ®Google Scholar
• Pinto BGG, Oliveira AER, Singh Y, et al. ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19. J Infect Dis. 2020;222(4):556–563. doi:10.1093/infdis/jiaa332
   PubMed Web of Science ®Google Scholar
• Chen L, Li X, Chen M, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097–1100. doi:10.1093/cvr/cvaa078
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–879. doi:10.1038/nm1267
   PubMed Web of Science ®Google Scholar
• Altmann DM, Boyton RJ. COVID-19 vaccination: the road ahead. Science. 2022;375(6585):1127–1132. doi:10.1126/science.abn1755
   PubMed Web of Science ®Google Scholar
• Khames Aga QA A, Alkhaffaf WH, Hatem TH, et al. Safety of COVID-19 vaccines. J Med Virol. 2021;93(12):6588–6594. doi:10.1002/jmv.27214
   PubMed Web of Science ®Google Scholar
• Zhuang C, Liu X, Chen Q, et al. Protection Duration of COVID-19 Vaccines: waning Effectiveness and Future Perspective. Front Microbiol. 2022;13:828806. doi:10.3389/fmicb.2022.828806
   PubMed Web of Science ®Google Scholar
• Kibongani Volet A, Scavone C, Catalán-Matamoros D, et al. Vaccine Hesitancy Among Religious Groups: reasons Underlying This Phenomenon and Communication Strategies to Rebuild Trust. Front Public Health. 2022;10:824560. doi:10.3389/fpubh.2022.824560
   PubMed Web of Science ®Google Scholar
• Rabie AM. Teriflunomide: a possible effective drug for the comprehensive treatment of COVID-19. Curr Res Pharmacol Drug Discov. 2021;2:100055. doi:10.1016/j.crphar.2021.100055
   PubMedGoogle Scholar
• Rabie AM, Abdalla M. Forodesine and Riboprine Exhibit Strong Anti-SARS-CoV-2 Repurposing Potential: in Silico and In Vitro Studies. ACS Bio Med Chem Au. 2022;2(6):565–585. doi:10.1021/acsbiomedchemau.2c00039
   PubMedGoogle Scholar
• Rabie AM, Abdalla M. Evaluation of a series of nucleoside analogs as effective anticoronaviral-2 drugs against the Omicron-B.1.1.529/BA.2 subvariant: a repurposing research study. Med Chem Res. 2023;32(2):326–341. doi:10.1007/s00044-022-02970-3
   PubMed Web of Science ®Google Scholar
• Rabie AM. Efficacious Preclinical Repurposing of the Nucleoside Analogue Didanosine against COVID-19 Polymerase and Exonuclease. ACS Omega. 2022;7(25):21385–21396. doi:10.1021/acsomega.1c07095
   PubMed Web of Science ®Google Scholar
• Rabie AM. Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles. Chem Biol Interact. 2021;343:109480. doi:10.1016/j.cbi.2021.109480
   PubMed Web of Science ®Google Scholar
• Eltayb WA, Abdalla M, Rabie AM. Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir “S-217622”: a Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species. ACS Omega. 2023;8(6):5234–5246. doi:10.1021/acsomega.2c03881
   PubMedGoogle Scholar
• Rabie AM. Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoViTris2020 and ChloViD2020): successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs. New J Chem. 2021;45:761–771. doi:10.1039/D0NJ03708G
   Web of Science ®Google Scholar
• Rabie AM, Eltayb WA. Potent Dual Polymerase/Exonuclease Inhibitory Activities of Antioxidant Aminothiadiazoles Against the COVID-19 Omicron Virus: a Promising In Silico/In Vitro Repositioning Research Study. Mol Biotechnol. 2023;1–20. doi:10.1007/s12033-022-00551-8
   PubMed Web of Science ®Google Scholar
• Rabie AM, Abdel-Dayem MA, Abdalla M. Promising Experimental Anti-SARS-CoV‑2 Agent “SLL-0197800”: the Prospective Universal Inhibitory Properties against the Coming Versions of the Coronavirus. ACS Omega. 2023;8(39):XXXXX–XXXXX. doi:10.1021/acsomega.2c08073
   Web of Science ®Google Scholar
• Rabie AM. Potent Inhibitory Activities of the Adenosine Analogue Cordycepin on SARS-CoV-2 Replication. ACS Omega. 2022;7(3):2960–2969. doi:10.1021/acsomega.1c05998
   PubMed Web of Science ®Google Scholar
• Rabie AM. New Potential Inhibitors of Coronaviral Main Protease (CoV-Mpro): strychnine Bush, Pineapple, and Ginger could be Natural Enemies of COVID-19. Int J New Chem. 2022;9(3):225–237.
   Google Scholar
• Seyed Hosseini E, Riahi Kashani N, Nikzad H, et al. The novel coronavirus Disease-2019 (COVID-19): mechanism of action, detection and recent therapeutic strategies. Virology. 2020;551:1–9. doi:10.1016/j.virol.2020.08.011
   PubMed Web of Science ®Google Scholar
• Shin YH, Jeong K, Lee J, et al. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry. Angew Chem Int Ed Engl. 2022;61(11):e202115695. doi:10.1002/anie.202115695
   PubMed Web of Science ®Google Scholar
• Bojadzic D, Alcazar O, Chen J, et al. Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. ACS Infect Dis. 2021;7(6):1519–1534. doi:10.1021/acsinfecdis.1c00070
   PubMed Web of Science ®Google Scholar
• Chen R, Lan Z, Ye J, et al. Cytokine Storm: the Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. Front Immunol. 2021;12:589095. doi:10.3389/fimmu.2021.589095
   PubMed Web of Science ®Google Scholar
• Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93(1):250–256. doi:10.1002/jmv.26232
   PubMed Web of Science ®Google Scholar
• Pandey A, Shen C, Feng S, et al. Cell biology of inflammasome activation. Trends Cell Biol. 2021;31(11):924–939. doi:10.1016/j.tcb.2021.06.010
   PubMed Web of Science ®Google Scholar
• Sharma BR, Kanneganti TD. NLRP3 inflammasome in cancer and metabolic diseases. Nat Immunol. 2021;22(5):550–559. doi:10.1038/s41590-021-00886-5
   PubMed Web of Science ®Google Scholar
• Pan P, Shen M, Yu Z, et al. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Nat Commun. 2021;12(1):4664. doi:10.1038/s41467-021-25015-6
   PubMed Web of Science ®Google Scholar
• Campbell GR, To RK, Hanna J, et al. SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway. iScience. 2021;24(4):102295. doi:10.1016/j.isci.2021.102295
   PubMed Web of Science ®Google Scholar
• Rodrigues TS, de Sá KSG, Ishimoto AY, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med. 2021;218(3):e20201707. doi:10.1084/jem.20201707
   PubMed Web of Science ®Google Scholar
• Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–e331. doi:10.1016/S2665-9913(20)30127-2
   PubMedGoogle Scholar
• Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393–e400. doi:10.1016/S2665-9913(20)30164-8
   PubMedGoogle Scholar
• Amin S, Aktar S, Rahman MM, et al. NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity. Microbes Infect. 2022;24(1):104913. doi:10.1016/j.micinf.2021.104913
   PubMed Web of Science ®Google Scholar
• Bonaventura A, Vecchié A, Dagna L, et al. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation. Inflamm Res. 2022;71(3):293–307. doi:10.1007/s00011-022-01540-y
   PubMed Web of Science ®Google Scholar
• Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842–844. doi:10.1038/s41591-020-0901-9
   PubMed Web of Science ®Google Scholar
• Zizzo G, Tamburello A, Castelnovo L, et al. Immunotherapy of COVID-19: inside and Beyond IL-6 Signalling. Front Immunol. 2022;13:795315. doi:10.3389/fimmu.2022.795315
   PubMed Web of Science ®Google Scholar
• Potere N, Batticciotto A, Vecchié A, et al. The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev Clin Immunol. 2021;17(6):601–618. doi:10.1080/1744666X.2021.1919086
   PubMed Web of Science ®Google Scholar
• van de Veerdonk FL, Netea MG. Blocking IL-1 to prevent respiratory failure in COVID-19. Crit Care. 2020;24(1):445. doi:10.1186/s13054-020-03166-0
   PubMed Web of Science ®Google Scholar
• Ganesan N, Baskaran R, Velmurugan BK, et al. Antrodia cinnamomea-An updated minireview of its bioactive components and biological activity. J Food Biochem. 2019;43(8):e12936. doi:10.1111/jfbc.12936
   PubMed Web of Science ®Google Scholar
• Kuang Y, Li B, Wang Z, et al. Terpenoids from the medicinal mushroom Antrodia camphorata: chemistry and medicinal potential. Nat Prod Rep. 2021;38(1):83–102. doi:10.1039/D0NP00023J
   PubMed Web of Science ®Google Scholar
• Senthil Kumar KJ, Gokila Vani M, Hsieh HW, et al. Antcins from Antrodia cinnamomea and Antrodia salmonea Inhibit Angiotensin-Converting Enzyme 2 (ACE2) in Epithelial Cells: can Be Potential Candidates for the Development of SARS-CoV-2 Prophylactic Agents. Plants. 2021;10(8):1736. doi:10.3390/plants10081736
   Google Scholar
• Chen CY, Chien SC, Tsao NW, et al. Metabolite Profiling and Comparison of Bioactivity in Antrodia cinnamomea and Antrodia salmonea Fruiting Bodies. Planta Med. 2016;82(3):244–249. doi:10.1055/s-0035-1558141
   PubMed Web of Science ®Google Scholar
• Huang HT, Wang SL, Nguyen VB, et al. Isolation and Identification of Potent Antidiabetic Compounds from Antrodia cinnamomea-An Edible Taiwanese Mushroom. Molecules. 2018;23(11):2864. doi:10.3390/molecules23112864
   PubMed Web of Science ®Google Scholar
• Chu YW, Yang PC, Yang SC, et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol. 1997;17(3):353–360. doi:10.1165/ajrcmb.17.3.2837
   PubMed Web of Science ®Google Scholar
• Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938;27(3):493–497. doi:10.1093/oxfordjournals.aje.a118408
   Google Scholar
• Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045. doi:10.2807/1560-7917.ES.2020.25.3.2000045
   PubMedGoogle Scholar
• Yen IC, Lin JC, Chen Y, et al. Antrodia Cinnamomea Attenuates Non-Alcoholic Steatohepatitis by Suppressing NLRP3 Inflammasome Activation In Vitro and In Vivo. Am J Chin Med. 2020;48(8):1859–1874. doi:10.1142/S0192415X20500937
   PubMed Web of Science ®Google Scholar
• Muñoz-Fontela C, Dowling WE, Funnell SGP, et al. Animal models for COVID-19. Nature. 2020;586(7830):509–515. doi:10.1038/s41586-020-2787-6
   PubMed Web of Science ®Google Scholar
• Shytaj IL, Fares M, Gallucci L, et al. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters. mBio. 2022;13(2):e0370521. doi:10.1128/mbio.03705-21
   PubMed Web of Science ®Google Scholar
• Leowattana W. COVID-19: potential Repurposing Drugs. Infect Disord Drug Targets. 2022;22(1):e110122191924. doi:10.2174/1871526521666210301143441
   PubMedGoogle Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-0
   PubMed Web of Science ®Google Scholar
• Hassanipour S, Arab-Zozani M, Amani B, et al. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021;11(1):11022. doi:10.1038/s41598-021-90551-6
   PubMed Web of Science ®Google Scholar
• Tao K, Tzou PL, Nouhin J, et al. SARS-CoV-2 Antiviral Therapy. Clin Microbiol Rev. 2021;34(4):e0010921. doi:10.1128/CMR.00109-21
   PubMed Web of Science ®Google Scholar
• Wahl A, Gralinski LE, Johnson CE, et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591(7850):451–457. doi:10.1038/s41586-021-03312-w
   PubMed Web of Science ®Google Scholar
• Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586–1593. doi:10.1126/science.abl4784
   PubMed Web of Science ®Google Scholar
• Sasaki M, Tabata K, Kishimoto M, et al. S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. Sci Transl Med. 2023;15(679):eabq4064. doi:10.1126/scitranslmed.abq4064
   PubMed Web of Science ®Google Scholar
• Wang N, Han S, Liu R, et al. Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus. Phytomedicine. 2020;79:153333. doi:10.1016/j.phymed.2020.153333
   PubMed Web of Science ®Google Scholar
• Fantini J, Di Scala C, Chahinian H, et al. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020;55(5):105960. doi:10.1016/j.ijantimicag.2020.105960
   PubMed Web of Science ®Google Scholar
• Razeghian-Jahromi I, Zibaeenezhad MJ, Lu Z, et al. Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure. Heart Fail Rev. 2021;26(2):371–380. doi:10.1007/s10741-020-10016-2
   PubMed Web of Science ®Google Scholar
• Issa H, Eid AH, Berry B, et al. Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19. Front Med. 2021;8:620990. doi:10.3389/fmed.2021.620990
   Web of Science ®Google Scholar
• Cantero-Navarro E, Fernández-Fernández B, Ramos AM, et al. Renin-angiotensin system and inflammation update. Mol Cell Endocrinol. 2021;529:111254. doi:10.1016/j.mce.2021.111254
   PubMed Web of Science ®Google Scholar
• Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020;181(4):905–913.e7. doi:10.1016/j.cell.2020.04.004
   PubMed Web of Science ®Google Scholar
• Ang L, Song E, Zhang J, et al. Herbal medicine for COVID-19: an overview of systematic reviews and meta-analysis. Phytomedicine. 2022;102:154136. doi:10.1016/j.phymed.2022.154136
   PubMed Web of Science ®Google Scholar
• Zhao Z, Li Y, Zhou L, et al. Prevention and treatment of COVID-19 using Traditional Chinese Medicine: a review. Phytomedicine. 2021;85:153308. doi:10.1016/j.phymed.2020.153308
   PubMed Web of Science ®Google Scholar
• Zhao Y, Deng S, Bai Y, et al. Promising natural products against SARS-CoV-2: structure, function, and clinical trials. Phytother Res. 2022;36(10):3833–3858. doi:10.1002/ptr.7580
   PubMed Web of Science ®Google Scholar
• Pérez-Vargas J, Shapira T, Olmstead AD, et al. Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics. Antiviral Res. 2023;209:105484. doi:10.1016/j.antiviral.2022.105484
   PubMed Web of Science ®Google Scholar
• ElNaggar MH, Abdelwahab GM, Kutkat O, et al. Aurasperone A Inhibits SARS CoV-2 In Vitro: an Integrated In Vitro and In Silico Study. Mar Drugs. 2022;20(3):179. doi:10.3390/md20030179
   PubMed Web of Science ®Google Scholar
• Alhadrami HA, Burgio G, Thissera B, et al. Neoechinulin A as a Promising SARS-CoV-2 Mpro Inhibitor: In vitro and In Silico Study Showing the Ability of Simulations in Discerning Active from Inactive Enzyme Inhibitors. Mar Drugs. 2022;20(3):163. doi:10.3390/md20030163
   PubMed Web of Science ®Google Scholar
• Liang XX, Zhang XJ, Zhao YX, et al. Aspulvins A-H, Aspulvinone Analogues with SARS-CoV-2 Mpro Inhibitory and Anti-inflammatory Activities from an Endophytic Cladosporium sp. J Nat Prod. 2022;85(4):878–887. doi:10.1021/acs.jnatprod.1c01003
   PubMed Web of Science ®Google Scholar
• Dai YJ, Wan SY, Gong SS, et al. Recent advances of traditional Chinese medicine on the prevention and treatment of COVID-19. Chin J Nat Med. 2020;18(12):881–889. doi:10.1016/S1875-5364(20)60031-0
   PubMed Web of Science ®Google Scholar
• Chuang SY, Chen CY, Yang SC, et al. 2,4-Dimethoxy-6-Methylbenzene-1,3-diol, a Benzenoid From Antrodia cinnamomea, Mitigates Psoriasiform Inflammation by Suppressing MAPK/NF-κB Phosphorylation and GDAP1L1/Drp1 Translocation. Front Immunol. 2021;12:664425. doi:10.3389/fimmu.2021.664425
   PubMed Web of Science ®Google Scholar
• Lu MK, Lee MH, Chao CH, et al. Physiochemical changes and mechanisms of anti-inflammation effect of sulfated polysaccharides from ammonium sulfate feeding of Antrodia cinnamomea. Int J Biol Macromol. 2020;148:715–721. doi:10.1016/j.ijbiomac.2020.01.110
   PubMed Web of Science ®Google Scholar
• Kim JS, Lee JY, Yang JW, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316–329. doi:10.7150/thno.49713
   PubMed Web of Science ®Google Scholar
• Amati F, Tonutti A, Huston J, et al. Glucocorticoid Therapy in COVID-19. Semin Respir Crit Care Med. 2023;44(1):100–117. doi:10.1055/s-0042-1759778
   PubMedGoogle Scholar
• Wang Y, Perlman S. COVID-19: inflammatory Profile. Annu Rev Med. 2022;73(1):65–80. doi:10.1146/annurev-med-042220-012417
   PubMedGoogle Scholar
• Conti P, Caraffa A, Gallenga CE, et al. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy. J Biol Regul Homeost Agents. 2020;34(6):1971–1975. doi:10.23812/20-1-E
   PubMed Web of Science ®Google Scholar
• Yen IC, Tu QW, Chang TC, et al. 4-Acetylantroquinonol B ameliorates nonalcoholic steatohepatitis by suppression of ER stress and NLRP3 inflammasome activation. Biomed Pharmacother. 2021;138:111504. doi:10.1016/j.biopha.2021.111504
   PubMed Web of Science ®Google Scholar
• Han C, Shen H, Yang Y, et al. Antrodia camphorata polysaccharide resists 6-OHDA-induced dopaminergic neuronal damage by inhibiting ROS-NLRP3 activation. Brain Behav. 2020;10(11):e01824. doi:10.1002/brb3.1824
   PubMed Web of Science ®Google Scholar
• Liu WH, Shi LS, Chung MC, et al. Antcamphin M Inhibits TLR4-Mediated Inflammatory Responses by Upregulating the Nrf2/HO-1 Pathway and Suppressing the NLRP3 Inflammasome Pathway in Macrophages. Am J Chin Med. 2019;47(7):1611–1626. doi:10.1142/S0192415X19500824
   PubMed Web of Science ®Google Scholar
• Huang TT, Wu SP, Chong KY, et al. The medicinal fungus Antrodia cinnamomea suppresses inflammation by inhibiting the NLRP3 inflammasome. J Ethnopharmacol. 2014;155(1):154–164. doi:10.1016/j.jep.2014.04.053
   PubMed Web of Science ®Google Scholar
• Reyes AZ, Hu KA, Teperman J, et al. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis. 2021;80(5):550–557. doi:10.1136/annrheumdis-2020-219174
   PubMed Web of Science ®Google Scholar
• Banerjee R, Perera L, Tillekeratne LMV. Potential SARS-CoV-2 main protease inhibitors. Drug Discov Today. 2021;26(3):804–816. doi:10.1016/j.drudis.2020.12.005
   PubMed Web of Science ®Google Scholar
• Vicenti I, Zazzi M, Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin Ther Pat. 2021;31(4):325–337. doi:10.1080/13543776.2021.1880568
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447–456.e11. doi:10.1016/j.cell.2021.12.032
   PubMed Web of Science ®Google Scholar
• Yang X, Wang X, Lin J, et al. Structure and Anti-Inflammatory Activity Relationship of Ergostanes and Lanostanes in Antrodia cinnamomea. Foods. 2022;11(13):1831. doi:10.3390/foods11131831
   PubMed Web of Science ®Google Scholar
• Achudhan D, Liu SC, Lin YY, et al. Antcin K Inhibits TNF-α, IL-1β and IL-8 Expression in Synovial Fibroblasts and Ameliorates Cartilage Degradation: implications for the Treatment of Rheumatoid Arthritis. Front Immunol. 2021;12:790925. doi:10.3389/fimmu.2021.790925
   PubMed Web of Science ®Google Scholar